Results 11 to 20 of about 2,023,245 (348)

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.

New England Journal of Medicine, 2022
BACKGROUND Neoadjuvant or adjuvant chemotherapy confers a modest benefit over surgery alone for resectable non-small-cell lung cancer (NSCLC). In early-phase trials, nivolumab-based neoadjuvant regimens have shown promising clinical activity; however ...
P. Forde, J. Spicer, Shun Lu, M. Provencio, T. Mitsudomi, M. Awad, E. Felip, S. Broderick, J. Brahmer, S. Swanson, K. Kerr, Changli Wang, T. Ciuleanu, G. Saylors, F. Tanaka, H. Ito, Keke Chen, M. Liberman, E. Vokes, J. Taube, C. Dorange, Junliang Cai, J. Fiore, A. Jarkowski, D. Balli, M. Sausen, D. Pandya, C. Calvet, N. Girard   +28 more
semanticscholar   +1 more source

Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer.

New England Journal of Medicine, 2023
BACKGROUND Standard first-line chemotherapy for endometrial cancer is paclitaxel plus carboplatin. The benefit of adding pembrolizumab to chemotherapy remains unclear.
R. Eskander, M. Sill, L. Beffa, Richard G. Moore, J. Hope, Fernanda B Musa, R. Mannel, M. Shahin, G. Cantuaria, E. Girda, C. Mathews, J. Kavecansky, Charles A Leath Iii, L. Gien, E. Hinchcliff, S. Lele, L. Landrum, F. Backes, R. O'Cearbhaill, T. Al Baghdadi, E. Hill, P. Thaker, V. John, S. Welch, A. Fader, M. Powell, C. Aghajanian   +26 more
semanticscholar   +1 more source

Systemic analysis of the AST results in medical organizations of the Russian Feder ation [PDF]

Клиническая микробиология и антимикробная химиотерапия, 2023
Objective. To analyse aggregated AST results for key microorganisms collected through the 2022 reports of chief specialists in clinical microbiology and antimicrobial resistance. Materials and Methods.
Vinogradova A.G., Kuzmenkov A.Yu., Trushin I.V., Sukhorukova M.V., Kozlov R.S.   +4 more
doaj   +1 more source

Severe anaphylaxis caused by intravenous anti‐cancer drugs

Cancer Medicine, 2021
Background The incidence and risk factors of severe anaphylaxis by intravenous anti‐cancer drugs are unclear, whereas those of milder reactions have been reported.
Nobuyuki Horita, Etsuko Miyagi, Taichi Mizushima, Maki Hagihara, Chiaki Hata, Yuki Hattori, Narihiko Hayashi, Kuniyasu Irie, Hideyuki Ishikawa, Yusuke Kawabata, Yosuke Kitani, Noritoshi Kobayashi, Nobuaki Kobayashi, Yusuke Kurita, Yohei Miyake, Kentaro Miyake, Senri Oguri, Ichiro Ota, Ayako Shimizu, Masanobu Takeuchi, Akimitsu Yamada, Kojiro Yamamoto, Norio Yukawa, Munetaka Masuda, Nobuhiko Oridate, Yasushi Ichikawa, Takeshi Kaneko   +26 more
doaj   +1 more source

Antimicrobial resistance of clinical isolates of Klebsiella pneumoniae and Escherichia coli in Russian hospitals: results of a multicenter epidemiological study [PDF]

Клиническая микробиология и антимикробная химиотерапия
Objective. To study the prevalence and mechanisms of antibiotic resistance, including carbapenemase production, in clinical isolates of Klebsiella pneumoniae and Escherichia coli isolated in different regions of Russia as part of the sentinel ...
Edelstein M.V., Shajdullina E.R., Ivanchik N.V., Dekhnich A.V., Mikotina A.V., Skleenova E.Yu., Sukhorukova M.V., Azyzov I.S., Shek E.A., Romanov A.V., Trushin I.S., Kuzmenkov A.Yu., Kozlov R.S.   +12 more
doaj   +1 more source

Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer

New England Journal of Medicine, 2018
BACKGROUND First‐line therapy for advanced non–small‐cell lung cancer (NSCLC) that lacks targetable mutations is platinum‐based chemotherapy. Among patients with a tumor proportion score for programmed death ligand 1 (PD‐L1) of 50% or greater ...
L. Gandhi, D. Rodríguez-Abreu, S. Gadgeel, E. Esteban, E. Felip, F. De Angelis, M. Dómine, P. Clingan, M. Hochmair, S. Powell, S. Cheng, H. Bischoff, N. Peled, F. Grossi, R. Jennens, M. Reck, R. Hui, E. Garon, M. Boyer, B. Rubio-Viqueira, S. Novello, T. Kurata, J. Gray, J. Vida, Ziwen Wei, Jing Yang, H. Raftopoulos, C. Pietanza, M. Garassino   +28 more
semanticscholar   +1 more source

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.

New England Journal of Medicine, 2022
BACKGROUND In an interim analysis of this phase 3 trial, the addition of pembrolizumab to chemotherapy resulted in longer progression-free survival than chemotherapy alone among patients with advanced triple-negative breast cancer whose tumors expressed ...
J. Cortés, H. Rugo, D. Cescon, S. Im, M. Yusof, C. Gallardo, O. Lipatov, C. Barrios, J. Peréz-García, H. Iwata, N. Masuda, M. Torregroza Otero, E. Gokmen, S. Loi, Zifang Guo, Xuan Zhou, V. Karantza, W. Pan, P. Schmid   +18 more
semanticscholar   +1 more source

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%

Journal of Clinical Oncology, 2021
PURPOSE We report the first 5-year follow-up of any first-line phase III immunotherapy trial for non–small-cell lung cancer (NSCLC). KEYNOTE-024 (ClinicalTrials.gov identifier: NCT02142738) is an open-label, randomized controlled trial of pembrolizumab ...
M. Reck, D. Rodríguez-Abreu, A. Robinson, R. Hui, T. Csőszi, A. Fülöp, M. Gottfried, N. Peled, A. Tafreshi, S. Cuffe, M. O'brien, Suman B. Rao, K. Hotta, T. Leal, J. Riess, E. Jensen, Bin Zhao, M. Pietanza, J. Brahmer   +18 more
semanticscholar   +1 more source

Principles of chemotherapy [PDF]

International Journal of Gynecology & Obstetrics, 2015
Chemotherapy plays a major role in the treatment of patients with gynecological malignancies. In general, chemotherapy has a smaller therapeutic window compared with drugs of other types; hence, the potential for severe adverse effects associated with chemotherapy has made appropriate patient and drug selection critical.
Åvall Lundqvist, Elisabeth, Fujiwara, Keiichi, Seoud, Muhieddine   +2 more
openaire   +4 more sources

Pembrolizumab plus Chemotherapy for Squamous Non–Small‐Cell Lung Cancer

New England Journal of Medicine, 2018
Background Standard first‐line therapy for metastatic, squamous non–small‐cell lung cancer (NSCLC) is platinum‐based chemotherapy or pembrolizumab (for patients with programmed death ligand 1 [PD‐L1] expression on ≥50% of tumor cells).
L. Paz-Ares, A. Luft, D. Vicente, A. Tafreshi, M. Gümüş, J. Mazières, B. Hermes, F. Senler, T. Csőszi, A. Fülöp, J. Rodríguez-Cid, Jonathan Wilson, S. Sugawara, T. Kato, K. Lee, Ying Cheng, S. Novello, B. Halmos, Xiaodong Li, G. Lubiniecki, B. Piperdi, D. Kowalski   +21 more
semanticscholar   +1 more source